Cushing's disease and melancholia

Stress

Volumn 4, Issue 2, 2001, Pages 91-119

  Condren, R M ^a   Thakore, J H ^a  

^a St Vincent's Hospital Ireland   (Ireland)

Author keywords

Cortisol; Cushing's disease; Hypothalamic pituitary adrenal axis; Melancholic depression; Physical complications

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DESMOPRESSIN; DEXAMETHASONE; GLUCOCORTICOID; GLUCOSE; HYDROCORTISONE; INSULIN; LEPTIN; NALOXONE; TETRACOSACTIDE; TRANSCORTIN; VASOPRESSIN;

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROSPINAL FLUID LEVEL; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CUSHING DISEASE; DEXAMETHASONE SUPPRESSION TEST; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; HORMONE BLOOD LEVEL; HORMONE URINE LEVEL; HUMAN; HYPERCORTISOLISM; HYPERTENSION; HYPOGLYCEMIA; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; LIFE EVENT; MELANCHOLIA; METABOLIC DISORDER; OSTEOPOROSIS; PRIORITY JOURNAL; SALIVA LEVEL;

EID: 0034803130     PISSN: 10253890     EISSN: None     Source Type: Journal    
DOI: 10.3109/10253890109115725     Document Type: Article

References (358)

1. A near miss - Osler's early description of Cushing's syndrome with, regrettably, no post-mortem examination
2. The dexamethasone suppression test: An overview of its current status in psychiatry
3. Gonadotropin release after administration of GnRH in depressed patients and healthy volunteers
4. 1-24) stimulation test in depressed patients and healthy subjects
5. Assessment of adrenal gland volume by computed tomography in depressed patients and healthy volunteers: A pilot study
6. Pituitary and adrenocortical responses to the ovine corticotropin releasing hormone in depressed patients and healthy volunteers
7. Multiple hormonal responses to insulin-induced hypoglycemia in depressed patients and normal volunteers
8. The assessment of abnormalities in hormonal responsiveness at multiple levels of the hypothalamic-pituitary-adrenocortical axis in depressive illness
9. Depressed affect, hopelessness, and the risk of ischaemic heart disease in a cohort of U.S. adults
10. Immunologic indices in Itsenko-Cushing disease
11. Elevated nocturnal profiles of serum leptin in patients with depression
12. Effects of electroconvulsive therapy on neuropsychological function and circulating levels of ACTH, cortisol, prolactin, and TSH in patients with major depressive illness
13. The dexamethasone suppression test for the diagnosis and prognosis in psychiatry: Commentary and review
14. The dexamethasone suppression test and depression. Approaches to the use of a laboratory test in psychiatry
15. Depression and cardiovascular diseases
16. Cushing's disease
17. Plasma cortisol secretion and REM period latency in adult endogenous depression
18. Endometrial cancer, obesity, and body fat distribution
19. Cognitive function in depression: A distinct pattern of frontal impairment in melancholia?
20. Stress hormones: Their interaction and regulation
21. In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: Relationship to dexamethasone suppression test results in patients
22. Hypercortisolaemia and hippocampal changes in depression
23. Hypothalamic-pituitary-gonadal axis in depressed premenopausal women: Elevated blood testosterone concentrations compared to normal controls
24. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia
25. Cerebrospinal fluid neuropeptides in mood disorder and dementia
26. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample
27. The immune hypothalamic-pituitary-adrenal axis
28. Melatonin, cortisol and ACTH in patients with major depressive disorder and healthy volunteers with special reference to the outcome of the dexamethasone suppression test
29. Effects of glucocorticoids and of growth hormone on serum leptin concentrations in man
30. Radioimmunoassay of ACTH in plasma
31. Cushing's syndrome
32. The associations between obesity, adipose tissue distribution and disease
33. Metabolic implications of body fat distribution
34. The regulation of adipose tissue distribution in humans
35. Psychological stress and endocrine functions: Blood levels of adrenocortical and thyroid hormones in acutely disturbed patients
36. Circadian cortisol rhythms in Cushing's disease
37. Human corticosteroid binding globulin
38. Low cholesterol concentrations and severe depressive symptoms in elderly people
39. 17-Ketosteroid excretion in a case of manic-depressive psychosis
40. Depression and memory impairment: A meta-analysis of the association, its pattern and specificity
41. Cognitive function and the dexamethasone suppression test in depression
42. Adrenal cortical activity in depressive illness
43. Diagnostic evaluation of Cushing's syndrome
44. Rate sensitive inhibition of ACTH release in depression
45. Psychoendocrine relationships in affective disorders
46. Urinary free cortisol excretion in depression
47. Pituitary-adrenal axis response to arginine vasopressin in patients with major depression
48. Plasma corticotropin-releasing factor in depressive disorders
49. The neuroendocrinology of depression and chronic stress
50. Glucocorticoids and glucocorticoid antagonists: Lessons from RU486
51. The concepts of stress and stress system disorders
52. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: Clinical implications
53. Factitious Cushing's syndrome
54. Plasma leptin levels do not change in patients with Cushing's disease shortly after correction of hypercortisolism
55. A chronobiological study of melatonin and cortisol secretion in depressed subjects: Plasma melatonin, a biological marker in major depression
56. Hostility and neuroticism among unselected essential hypertensives
57. Cushings syndrome: A psychiatric study of 29 patients
58. Effort and cognition in depression
59. Depressive symptoms and other psychosocial factors as predictors of stroke in the elderly
60. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide, and renal function in normal man
61. Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin
62. Cushing's syndrome: A review of diagnostic tests
63. The overnight dexamethasone test is a worthwhile screening procedure
64. The Basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism)
65. Effect of dexamethasone on plasma leptin concentration in lean and obese humans: A randomized placebo-controlled study
66. Expression of glucocorticoid receptor gene isoforms in corticotropin-secreting tumours
67. Cushing's syndrome and hypertension
68. Salivary testosterone levels and major depressive illness in men
69. Naloxone test distinguishes pituitary ACTH-dependent Cushing's disease (CD) from major depressive disorder (MDD) and chronic alcoholism (ALC)
70. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin releasing hormone and arginine vasopressin in patients with major depression
71. Brain corticosteroid receptor balance in health and disease
72. Stress and cognition: Are corticosteroids good or bad guys?
73. Corticosteroid-binding globulin is not decreased in depressed patients
74. Plasma leptin in depressed patients and healthy controls
75. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls
76. Induction of of gene expression by corticosteroids is accompanied by weight loss and reduced food intake
77. Menstrual problems in women with primary affective illness
78. Mutation and expression analysis of corticotropin-releasing factor 1 receptor in adrenocorticotropin-secreting pituitary adenomas
79. Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: Evidence of enhanced vasopressinergic responsivity
80. Psychopathology in patients with endogenous Cushings syndrome: "atypical" or melancholic features
81. Effects of adrenal cortex hormones on Limbic structures: Some experimental and clinical correlations related to depression
82. The role of blood osmolality and volume in regulating vasopressin secretion
83. Depression and the risk for onset of type 2 diabetes
84. Neuropsychological impairments in unipolar depression: The influence of perceived failure on subsequent performance
85. Morbidity and mortality in Cushing's disease: An epidemiological approach
86. Hoplessness and risk of mortality and incidence of myocardial infarction and cancer
87. Stressful life events and affective disorders inhibit pulsatile LH secretion in hypothalamic amenorrhea
88. Life events and depression. A replication
89. Affective disorders and endocrine disease
90. A follow-up study of elderly depressives and Alzheimer-type dementia-relationship with DST status
91. Vitamin D metabolites and parathyroid hormone in Cushing's syndrome: Relationship to calcium and phosphorus homeostasis
92. Depression predicts cardiovascular disease in men: The precursors study
93. Cognitive decline in patients with Cushing's syndrome
94. Plasma lipid levels and psychologic characteristics in men
95. Severe kyphosis secondary to glucocorticoi-induced osteoporosis in a young adult with Cushing's disease. A case report and literature review
96. Depression and hypertension
97. Decreased delta-sleep-inducing peptide in patients with Cushings syndrome
98. Carbohydrate and lipid metabolism in endogenous hypercortisolism: Shared features with metabolic syndrome x and NIDDM
99. The hypothalamic-pituitary-adrenocortical system and sleep in man
100. Serial cerebrospinal fluid corticotropin-releasing hormone concentrations in healthy and depressed humans
101. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment
102. Cushing's disease as a psychosomatic disorder
103. Cushing's disease as a psychosomatic disorder
104. Stimulation of the pituitary-adrenal axis with a low dose (Arg8)-vasopressin in depressed patients and healthy subjects
105. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor
106. Responses to corticotropin-releasing hormone in hypercortisolism of depression and Cushing's disease: Pathophysiological and diagnostic implications
107. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress
108. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress
109. The endocrinology of melancholic and atypical depression: Relation to neurocircuitry and somatic consequences
110. Cortisol secretion in endogenous depression: 11. Time related function
111. Decreased bone mineral density in medicated psychiatric patients
112. Serum testosterone levels in women with Cushing's disease
113. Socio-ecological stress, suppressed hostility, skin color and black-white blood pressure: Detroit
114. Diagnostic categorization of psychiatric disturbance in Cushing's syndrome
115. Exacrebation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone
116. Relationship of psychosocial factors to coronary heart disease in the Framingham study. I. Methods and risk factors
117. Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome
118. The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders
119. Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects
120. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: Response to amitriptyline treatment
121. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression
122. ACTH and multisteroid responses to corticotropin-releasing factor in depressive illness: Relationship to multisteroid responses after ACTH stimulation and dexamethasone suppression
123. ACTH, cortisol, and corticosterone output after ovine corticotropin-releasing factor challenge during depression and after recovery
124. Multi-steroid analysis after DST in depressed patients - A controlled study
125. Antidepressants and hypothalamic-pituitary-adrenocortical regulation
126. The corticosteroid receptor hypothesis of depression
127. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression
128. Occupational stress and health among factory workers
129. Altered circadian blood pressure rhythm in patients with Cushing's syndrome
130. Immune correlates of depression
131. Clinical effects of cortisol synthesis inhibitors on treatment-resistant depression
132. Naloxone induced ACTH release in man is inhibited by clonidine
133. The role of the hippocampus in feedback regulation of the hypothalamic-pituitary adrenocortical axis
134. Enhanced adrenal sensitivity to exogenous cosyntropin (ACTH 1-24) stimulation in major depression: Relationship to dexamethasone suppression test results
135. Psychiatric manifestations of Cushing's syndrome: Response to lowering of plasma cortisol
136. Hormonal and metabolic rhythms in Cushing's syndrome
137. Are symptoms of anxiety and depression risk factors for hypertension?
138. Relationships between depressive symptoms, anxiety, alcohol consumption, and blood pressure: Results from the CARDIA study
139. The incidence of hypertension and associated factors: The Israel ischaemic heart disease study
140. Memory and meta-memory functioning among depressed patients
141. Consistent reduction of ACTH responses to stimulation with CRH, vasopressin and hypoglycaemia in patients with major depression
142. Cortisol and hypertension
143. Cushing's syndrome, tryptophan and depression
144. A prospective study of psychiatric and psychological aspects of Cushing's syndrome
145. High leptin concentrations in serum of very obese children are further stimulated by dexamethasone
146. Stress- and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults
147. Regional adiposity and morbidity
148. Skeletal recovery after treatment of Cushing's: Still room for improvement
149. Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: Potential clinical implications
150. Insulin tolerance test: Human growth hormone response and insulin resistance in unipolar depressed, bipolar depressed and control subjects
151. Cushing's syndrome and exogenous glucocorticoid hypertension
152. Neuropsychological functioning and MRI signal hyperintensities in geriatric depression
153. Sleep EEG stages and plasma growth hormone concentration in states of endogenous and exogenous hypercortisolemia or ACTH elevation
154. Absence of nocturnal elevation of plasma prolactin concentrations in Cushing's disease
155. Pathophysiology of Cushing's disease
156. Immune regulation in Cushing's syndrome: Relationship to hypothalamic-pituitary-adrenal axis hormones
157. Differential diagnosis and pathophysiology of Cushing's syndrome and primary affective disorder
158. Two roads to rapid eye movement latency
159. Recurrent thromboembolism as a hallmark of Cushing's syndrome
160. Laboratory evaluation for Cushing's syndrome in psychiatric patients with cortisol nonsuppression following the overnight dexamethasone suppression test
161. The plasma sugar, free fatty acid, cortisol, and growth hormone response to insulin, and the comparison of this proceedure with other tests of pituitary and adrenal function. 11. In patients with hypothalamic or pituitary dysfunction or anorexia nervosa
162. Obesity, adipose tissue distribution and health in women-results from a population study in Gothenburg, Sweden
163. Obesity, adipose tissue distribution and health in men: The study of men born in 1913
164. Short-term dexamethasone treatment increases plasma leptin independently of changes in insulin sensitivity in healthy women
165. Pharmacology and clinical perspectives of vasopressin antagonists
166. Serum immunore-active-leptin levels are increased in patients with Cushing's syndrome
167. Plasma adrenocorticotropin is more sensitive than transcortin production or thymus weight to inhibition by corticosterone in rats
168. Total and free testosterone in depressed men
169. Differentiation of depressive subtypes by insulin insensitivity in the recovered phase
170. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function
171. The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness
172. 24-Hour profiles of adrenocorticotropin, cortisol, and growth hormone in major depressive illness: Effect of antidepressant treatment
173. Waist to hip ratio and psychosocial factors in adults with insulin-dependent diabetes mellitus: The Pittsburgh Epidemiology of Diabetes Complications study
174. Changes in body composition and adipose tissue distribution after treatment of women with Cushing's syndrome
175. Psychiatric phenomenology in Cushing's disease
176. Working memory is more sensitive than declarative memory to the acute effects of corticosteroids: A dose-response study in humans
177. Reversible gonadotropin deficiency in male Cushing's disease
178. Manifestations cardiovasculaires et anomalies lipidiques au cours du syndrome de Cushing
179. A multivariate study of simultaneous escape from suppression by dexamethasone of urinary free cortisol, plasma cortisol, adrenocorticotropic hormone and beta-endorphin in melancholic patients
180. Lower degree of esterification of serum cholesterol in depression: Relevance for depression and suicide research
181. Lower serum transcortin (CBG) in major depressed females: Relationships with baseline and postdexamethasone cortisol values
182. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: Relationship with immune-inflammatory markers
183. The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome
184. Cortisol and adrenocorticotropin response to desmopressin in women with Cushing's disease compared to depressive illness
185. Mortality among patients with involutional melancholia
186. Psychiatric morbidity and hostility in hypertension
187. Hypertension: Psychological aspects and diagnostic impact in a clinical trial
188. Normal bone mineral density following cure of Cushings syndrome
189. Glucocorticoid-dependent hypertension
190. The brain as a target for adrenocortical steroids: Cognitive implications
191. Natural killer cell activity in the peripheral blood of patients with Cushing's syndrome
192. A review of psychoendocrine research on the pituitary-adrenal cortical system
193. Glucocorticoid regulation of leptin synthesis and secretion in humans: Elevated leptin levels in Cushing's syndrome
194. Memory impairment in Cushing's disease
195. Body fat distribution measured with CT: Correlations in healthy subjects, patients with anorexia nervosa and patients with Cushing's syndrome
196. Paradoxical effects of adrenal steroids on the brain: Protection versus degeneration
197. Re-examination of the glucocorticoid hypothesis of stress and aging
198. The diurnal variation of plasma cortisol levels in depression
199. Stimulation of the pituitary-adrenal axis with arginine vasopressin in patients with depression
200. Luteinizing hormone pulse characteristics in depressed women
201. Differential response of plasma glucose, amino acids and non-esterified fatty acids in depressed patients
202. Dexamethasone induces an acute and sustained rise in circulating leptin levels in normal human subjects
203. Mediation of the stress response by the hypothalamic-pituitary-adrenal axis
204. Bone mineral density in women with depression
205. Risk factors for brain infarction in patients with Cushing's disease. Case reports
206. The overnight dexamethasone test is the proceedure of choice in screening for Cushing's syndrome
207. Pulsatile rhythms of adrenocorticotropin (ACTH) and cortisol in women with endogenous depression: Evidence for increased ACTH pulse frequency
208. Colocalization of corticotropin-releasing factor and vasopressin in the paraventricular nucleus of the human hypothalamus
209. Steroids and depression
210. Response to steroid suppression in major depression resistant to antidepressant therapy
211. Possible use of glucocorticoid receptor antagonists in the treatment of major depression; preliminary results using RU 486
212. Affective disorders and mortality
213. The relationship of depression to cardiovascular disease
214. Relative insulin insensitivity and cortisol secretion in depressed patients
215. Elevated concentrations of corticotropin releasing factor-like immunoreactivity in depressed patients
216. Adrenal gland enlargement in major depression. A computed tomographic study
217. Corticotropin-releasing factor and adrenal function in major depression
218. Diabetes and adrenal disease
219. Dose-dependent cortisol-induced increases in plasma leptin concentration in healthy humans
220. Decreased memory performance in healthy humans induced by stress-level cortisol treatment
221. A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing's syndrome
222. The differentiation of depression from dementia by temporal lobe magnetic resonance imaging
223. Clinical and magnetic resonance imaging correlates of hypothalamic-pituitary-adrenal axis function in depression and Alzheimer's disease
224. Temporal lobe magnetic resonance imaging can differentiate Alzheimer's disease from normal ageing, depression, vascular dementia and other causes of cognitive impairment
225. Studies on pituitary-gonadal function in patients with Cushing's syndrome
226. Treatment of major depression with metyrapone and hydrocortisone
227. Insulin resistance in patients with depression and its changes in the clinical course of depression: A report on three cases using the minimal model analysis
228. Serum lipid concentrations in patients with major depressive disorder
229. Cushing's syndrome
230. The adrenal cortex
231. Chronic disease in former college students. VIII. Characteristics in youth predisposing to hypertension in later years
232. 24-Hour profiles of blood pressure and heart rate in Cushing's syndrome. Evidence for differential control of cardiovascular variables by glucocorticoids
233. A single midnight serum cortisol measurement distinguishes Cushing's syndrome from pseudo-Cushing states
234. Association of low serum total cholesterol with major depression and suicide
235. Life events and social stress
236. Life events, social support and depression
237. Characterization of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue
238. Pituitary-adrenal axis rhythm disturbances in psychiatric depression
239. Differences in plasma ACTH and cortisol between depressed patients and normal controls
240. Association between post-dexamethasone cortisol level and blood pressure in depressed inpatients
241. The natural history of Cushing's syndrome
242. Depression, psychotropic medication, and risk of myocardial infarction: Prospective data from the Baltimore ECA follow-up
243. Increased number of vasopressin and oxytocin-expressing neurones in the paraventricular nucleus of the hypothalamus in depression
244. Increased numbers of corticotropin-releasing hormone expressing neurones in the hypothalamic paraventricular nucleus of depressed patients
245. Corticotropin-releasing factor and adrenocorticotropic hormone as potential central mediators of OB effects
246. Hypertension and DSM 111 depression in psychiatric outpatients
247. Banting Lecture 1988. Role of insulin resistance in human disease
248. Gluco-corticoid hormone binding in human adipose tissue
249. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome
250. Steroid hormone receptors in human adipose tissues
251. Psychopathology in Cushing's syndrome
252. Regulation of ACTH and cortisol in depression
253. Diagnosis and treatment in endocrinology and psychiatry
254. Evidence for physiological effects of hypercortisolemia in psychiatric patients
255. Sleep research in affective illness: State of the art circa
256. The DST as a predictor of outcome in depression: A meta-analysis
257. Concurrent observations of behavior changes and of adreno-cortical variations in a cyclothymic patient during a period of 12 months
258. A study of neuroticism and casual arterial blood pressure
259. Cushing's syndrome-killing disease: Discriminatory value of signs and symptoms aiding early diagnosis
260. Mental distress, obesity and body fat distribution in middle-aged men
261. Psychiatric ill-health of women and its relationship to obesity and body fat distribution
262. The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke
263. Pre-and post-dexamethasone plasma ACTH levels in depressed patients and normal controls
264. CSF corticotropin-releasing hormone in depressed patients and normal control subjects
265. Effortful and automatic cognitive processes in depression
266. Neuroendocrine aspects of primary endogenous depression, cortisol secretory dynamics in patients and matched controls
267. Neuroendocrine aspects of primary endogenous depression VIII. Pituitary-gonadal axis activity in male patients and matched control subjects
268. Adrenal gland volume in major depression. Increase during the depressive episode and decrease with successful treatment
269. Cortisol hypersecretion and cognitive impairment in depression
270. Neuroendocrine abnormalities in depressive illness
271. Transient increase in obese gene expression after food intake or insulin administration
272. Why stress is bad for your brain
273. Inhibition of interleukin-2-mediated lymphocyte activation in patients with Cushing's syndrome: A comparison with hypocortisolemic patients
274. The glucocorticoid sensitivity of lymphocytes changes according to the activity of the hypothalamic-pituitary-adrenocortical system
275. Visceral obesity and breast cancer risk
276. Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness
277. A comparison of adrenal cortical function in patients with depressive illness and Cushings disease
278. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression, and in normal controls
279. Identification of targets of leptin action in rat hypothalamus
280. Low lumbar bone mineral density in patients with major depression
281. Testosterone, gonadotropin, and cortisol secretion in male patients with major depression
282. Lumbar bone mineral density in patients with major depression: Evidence of increased bone loss at follow-up
283. The synacthen test in depressive illness
284. Vasopressin and the regulation of the hypothalamic-pituitary-adrenal axis function: Implications for the pathophysiology of depression
285. Circadian analysis of plasma cortisol levels before and after dexamethsaone levels in depressed patients
286. Hippocampal atrophy in recurrent major depression
287. The effect of in- or outpatient status on the association of EEG sleep data with post-dexamethasone cortisol levels in depressed patients
288. EEG sleep in Cushing's syndrome: Comparison with patients with major depressive disorder
289. T lymphocytes and plasma inhibitory factor in ACTH-dependent Cushing's patients
290. Cognitive impairment and cortisol resistance to dexamethasone suppression in elderly depression
291. Cognitive sequelae of hypothalamic-pituitary-adrenal (HPA) dysregulation in depression
292. Thromboembolic complications, heparin treatment in increase in coagulation factors in Cushing's syndrome
293. Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP
294. Thrombolic complications in Cushing's syndrome
295. Plasma testosterone profiles in Cushings syndrome
296. Effect of high blood pressure treatment and awareness on emotional well being
297. CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing's syndrome
298. Stressful life events in the pathogenesis of Cushing's syndrome
299. Ketoconazole treatment in Cushing's syndrome: Experience in 34 patients
300. A role for life events in the pathogenesis of Cushing's disease
301. Course of depression in Cushing's syndrome: Response to treatment and comparison to Graves' disease
302. Serotonin, Cushing's disease, and depression
303. Clinical correlates of major depression in Cushings disease
304. Depressed mood and other psychiatric manifestations of Cushing's syndrome: Relationship to hormone levels
305. Neuropsychiatric manifestations of patients with Cushing's syndrome
306. Cushing's syndrome after treatment: Changes in cortisol and ACTH levels, and amelioration of the depressive syndrome
307. Phenomenology and family history of affective disorder on Cushing's disease
308. Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome
309. Personality changes in Cushing's syndrome
310. Pretreatment DST and hypothalamic-pituitary-adrenocorticaI function in depressed patients and comparison groups
311. Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing's syndrome
312. Acute and prolonged administration of glucocorticoids (methylprednisolone) does not affect plasma leptin concentrations in humans
313. Cortisol synthesis inhibition: A new treatment strategy for the clinical and endocrine manifestations of depression
314. Effects of antidepressant treatment on corticotropin-induced cortisol responses in patients with melancholic depression
315. Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography
316. Electroencephalographic sleep profiles before and after cognitive behaviour therapy of depression
317. The anterior pituitary
318. Neuropsychiatric aspects of Cushings syndrome
319. The association of elevated plasma cortisol and early athersclerosis as demonstrated by coronary angiography
320. Assessment of cortisol and ACTH responses to the desmopressin test in patients with Cushing's syndrome and simple obesity
321. Physiology of the hypothalamic-pituitary-adrenal axis in health and dysregulation in psychiatric and autoimmune disorders
322. Hypothalamic-pituitary-gonadal axis in major depressive disorders
323. Effect of general excitement and of fighting on some ductless glands in male albino rats
324. Obesity results as a consequence of glucocorticoid-induced leptin resistance
325. Plasma levels of arginine vasopressin elevated in patients with major depression
326. Neuropsychological performance and plasma cortisol, arginine vasopressin and oxytocin in patients with major depression
327. Androgen deficit and osteoporosis in depressed female patients
328. Structure and function of the adrenal cortex
329. Cortisol response to a combined dexamethasone-human corticotropin-releasing hormone challenge in patients with depression
330. Effects of age on the cortisol response to human corticotropin-releasing hormone in patients pretreated with dexamethasone
331. Cushing's syndrome
332. Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease
333. Cognitive processes in depression
334. Leptin secretion in Cushing's syndrome: Preservation of diurnal rhythm and absent response to corticotropin-releasing hormone
335. Childhood sexual abuse as a risk factor for depression in women: Psychosocial and neurobiological correlates
336. Psychiatric aspects of hypertension
337. Neuropsychological deficits in Cushing's syndrome
338. Major pro-vasopressin-expressing and pro-deficient subpopulations of corticotropin-releasing hormone neurones in normal rats. Differential distributions within the paraventricular nucleus
339. Determinants of serum leptin levels in Cushing's syndrome
340. Waist to hip ratio in middle-aged women: Associations with behavioral and psychosocial factors and with changes in cardiovascular risk factors
341. DST nonsuppressor status: Relationship to specific aspects of the depressive syndrome
342. Insulin resistance after oral glucose tolerance testing in patients with major depression
343. Arginine vasopressin in Cushing's disease
344. Cognitive effects of corticosteroids
345. Ketoconazole administration in hypercortisolaemic depression
346. Antiglucocorticoid treatment of depression: Double-blind ketoconazole
347. Treatment of depression with antiglucocorticoid drugs
348. Glucose metabolism in unipolar depression
349. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration: A new test to distinguish Cushing's syndrome from pseudo-Cushing's states
350. Glucocorticoid action and the clinical features of Cushing's syndrome
351. Plasma ACTH levels in primary depression: Relationship to the 24-hour dexamethasone suppression test
352. Endocrine disorders and body fat distribution
353. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease